
STOK Stock Forecast & Price Target
STOK Analyst Ratings
Bulls say
Stoke Therapeutics Inc. has received an optimistic adjustment in its revenue projections for zorevunersen, reflecting increased expectations of well-received uptake, with target revenue estimates rising from $22 to $32 for its anticipated FY28 launch. Data from Phase I/II studies indicate that zorevunersen may significantly reduce seizures while providing cognitive benefits, thereby supporting its potential for disease modification in Dravet syndrome and de-risking future Phase 3 trials. Additionally, should the FDA provide expedited approval for zorevunersen, there exists potential for further upside, with target estimates possibly reaching the low-$40s, enhancing the overall outlook for Stoke Therapeutics' market position.
Bears say
Stoke Therapeutics Inc's stock faces a negative outlook primarily due to concerns regarding the protection of its intellectual property, as the potential failure to secure or extend key patents could adversely impact the company's asset valuation and market success. Additionally, despite some promising developments, the company operates in a competitive landscape for Dravet syndrome treatments, where multiple therapies have already gained significant market share. Lastly, the bleak natural history of the disease, characterized by persistent cognitive and seizure challenges, adds to the uncertainty surrounding the efficacy and market adoption of the company's lead product, zorevunersen.
This aggregate rating is based on analysts' research of Stoke Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
STOK Analyst Forecast & Price Prediction
Start investing in STOK
Order type
Buy in
Order amount
Est. shares
0 shares